CD8A and neoplasm: The expansion of peripheral blood cytotoxic CD8+ T cells in PDAC patients resulted in a decrease of TCR clonal diversity, suggesting that PDAC patients may retain a specific immune response to potential novel tumor antigens in PDAC that could be valuable for therapeutic targeting.